Additional Relevant Details
IMGN779 contains a CD33-targeting antibody - enabling it to bind to AML cells - with a powerful cancer-killing agent attached to kill them. IMGN779 is the first ADC to utilize one of ImmunoGen's new family of indolino-benzodiazepine cancer-killing agents, which the Company calls IGNs. DNA-alkylating IGNs have been designed to be ultra-potent, yet provide the tolerability necessary for ongoing retreatment.

The IMGN779 Phase 1 trial in CD33-positive AML will assess two alternative dosing schedules - weekly and biweekly administration - concurrently in its dose-finding stage. The selected dose and schedule will then be used in the two planned expansion cohorts: one assessing IMGN779 in patients with AML in first relapse and one assessing it in patients with relapsed/refractory AML.